ArticleScientific reports2025
Baicalin alleviates H
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- MMP8 exacerbates sepsis-induced pulmonary vascular leakage by disruption of endothelial VE-cadherin through ERK signalling.Molecular biomedicine · 2026Article
- Liensinine Ameliorating Oxidative Damage to Vascular Endothelium In Vitro via Upregulating eNOS and Nrf2/HO-1 Signaling.Food science & nutrition · 2026Article
- Baicalin: A comprehensive review of its molecular mechanisms and pharmacological activities.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Oxidative Stress in Pathogenesis of Preeclampsia: Mechanistic and Clinical Insights.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Preeclampsia (PE) is a leading cause of morbidity and mortality among pregnant women, postpartum mothers, and perinatal infants worldwide. Currently, there are no effective pharmacological interventions for the prevention or treatment of PE. Oxidative stress in vascular endothelial cells represents a key pathophysiological mechanism underlying PE. Baicalin, a flavonoid compound derived from the traditional Chinese medicine Scutellaria baicalensis, exhibits anti-inflammatory, antioxidant, antiapoptotic, and immunoregulatory properties. However, its potential application in PE remains insufficiently investigated. In vitro experiments were conducted to establish an oxidative stress model using human umbilical vein endothelial cells (HUVECs) exposed to hydrogen peroxide. Transcriptomic analysis was employed to identify genes significantly expressed differently. The effects of baicalin on HUVEC viability were assessed using the CCK-8 assay. Myeloperoxidase (MPO) levels were quantified via ELISA and colorimetric assays; while, the expression of MAPK/ERK1/2 signaling pathway components was analyzed using RT-qPCR and Western blotting. Cell apoptosis was evaluated by flow cytometry. Clinical studies have shown elevated MPO levels in the peripheral blood of patients with PE. Transcriptomic analysis identified the MAPK/ERK1/2 signaling pathway as a central pathway associated with oxidative stress model. Exposure to H
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.